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Abstract
TLR4 agonists can be used as adjuvants to trigger innate immune responses of antigen-presenting
cells (APCs) such as dendritic cells (DCs) to enhance vaccine-specific immunity. Adjuvant effects
of TLR4 agonists are mediated by downstream signaling controlled by both MyD88 and TRIF
adapter proteins. In this study, we investigated the adjuvanting capacity of glucopyranosyl lipid A
(GLA), a chemically synthesized TLR4 agonist, to boost antigen-specific immunity elicited by
DC-directed lentiviral vectors (DC-LV). We found that stimulation by this agonist in vitro can
activate DCs in a TLR4-dependent manner. The agonist can significantly boost DC-LV-induced
humoral and cellular immune responses, resulting in better antitumor reactions in response to
tumor challenges. We observed that the adjuvant-mediated enhancement of cytotoxic CD8+ T cell
responses is CD4+ T cell-dependent and determined that in vitro the agonist stimulation involves
the participation of both MyD88 and TRIF pathways to activate DCs. In vivo immunization study
however revealed that adjuvant effects depend more on the MyD88 signaling as TRIF-/- mice but
not MyD88-/- mice were able to maintain the enhanced CD8+ T cell responses upon DC-LV
immunization. Thus, our study supports the use of this TLR4 agonist as a potent adjuvant
candidate for boosting DC-LV immunization.
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1. Introduction
There has been a growing interest in utilizing lentiviral vectors (LVs) as vaccine carriers to
elicit antigen-specific humoral and cellular immune responses [1-4]. LVs present several
desirable features of a virus-based vaccine vector [5]: they are able to transduce both
dividing and non-dividing cells [6], capable of carrying large transgenes (up to 8 kb), and
low in pre-existing anti-vector immunity [7], and they are currently being evaluated in
human gene therapy trials for a wide range of human diseases [8]. Many studies have
demonstrated the promise of LVs to generate vaccine-specific immunity targeting a broad
range of infectious diseases and cancer [1, 9]. Although various routes of vaccine
administration have been investigated and compared [10-12], subcutaneous injection
remains the most potent and practical means for LVs to stimulate transgene-specific immune
responses. Recent reports have convincingly shown that a subcutaneous injection of LVs can
result in genetic modification of skin-derived dendritic cells (DCs) to have prolonged
antigen expression and presentation [13-15]. Their subsequent migration to skin-draining
lymph nodes and priming of the repertoire T cells are the major mechanism of action for the
resulting immune responses to the delivered antigens. Because of the essential role of DCs
in LV-mediated immunization, considerable effort has been devoted to developing LVs
capable of targeting DCs to improve vaccine efficacy and safety [1, 16-22]. We have
reported a targeting transduction system, in which the human immunodeficiency virus-1
(HIV-1)-based LV is enveloped with a mutant Sindbis virus glycoprotein (SVGmu) that,
when injected subcutaneously into mice, can target DCs through its selective recognition of
the attachment receptor DC-SIGN, a protein predominantly expressed on the DC surface
[23]. Immunization with this vector system resulted in durable immune responses to several
delivered immunogens and required only a modest dose of vector administration [23-26].
Our previous in vitro study showed a slight maturation of bone marrow-derived DCs
(BMDCs) upon exposure to this DC-directed LV (DC-LV) system [23], presumably due to
the interaction between SVGmu and DC-SIGN, and the transduction-mediated DC
activation via Toll-like receptors [27-29]. We postulated that DC-stimulating molecular
adjuvants such as agonists for TLR family proteins, when co-administered with DC-LV,
could further improve the vaccine efficacy. The mammalian TLRs are a group of pattern
recognition receptors expressed by innate immune cells and can be stimulated by structural
motifs known as pathogen-associated molecular patterns (PAMPs) contained by bacteria,
viruses, and fungi [30-32]. These stimulations can trigger downstream signal transduction
pathways such as nuclear factor (NF)-κB and interferon regulatory factor (IRF), which will
activate antigen-presenting cells (APCs) and promote inflammatory responses [31, 33, 34].
Among various known TLRs, TLR4 is the only one capable of inducing two distinct
signaling pathways [32, 35]: 1) the MyD88-dependent pathway to activate NF-κB signaling
and be responsible for induction of proinflammatory cytokines; 2) the TRIF-dependent
pathway to mediate the activation of Type I interferons. Studies have shown that the ability
to induce both pathways is essential for maximizing the immunostimulatory potentials of
DCs [36]. The most widely known TLR4 agonist is lipopolysaccharide (LPS) that presents
in the outer membrane of Gram-negative bacteria. Monophosphoryl lipid A (MPL) is a
derivative of LPS exacted from Salmonella minnesota R595 [37] and exhibits only ~0.1% of
the inflammatory toxicity of LPS [38, 39]. When used as an adjuvant, MPL enhances
immunogen-specific immune responses by promoting the development of Th1 CD4+ T cells
[40]. MPL has been approved as a component of adjuvant formulation for vaccines against
human papilloma virus (HPV) and hepatitis B virus (HBV) [40]. Recently a synthetic TLR4
agonist, glucopyranosyl lipid A (GLA), has emerged as a more pure and chemically defined
molecular adjuvant, in contrast to the heterogeneous mixture of MPL extracted from bacteria
[41]. GLA has been demonstrated to be potent for assisting the generation of Th1-biased
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immune responses in experimental vaccines against tuberculosis [42], leishmaniasis [43],
influenza [44], and malaria [45, 46]. It is currently being evaluated as an adjuvant in phase I
clinical trials of an influenza virus vaccine [47].
In this report, we explore this TLR4 agonist as an adjuvant for immunization delivered by a
DC-LV encoding the chicken ovalbumin (OVA) antigen. We show that GLA can activate
BMDCs in vitro and significantly improve the immune responses in vivo by increasing the
populations of both antigen-specific CD8+ and CD4+ T cells and improving the titers of
various antibody isotypes specific for OVA. These enhancements resulted in improved
protection against the growth of tumors yielding better survival rates in both prophylactic
and therapeutic tumor challenge models. Moreover, we also found that the elevated CD8+ T
cell responses provided by GLA are CD4+ T cell-dependent. Although the in vitro activation
of DCs by GLA was observed to be mediated by both MyD88- and TRIF-dependent
pathways, our DC-LV immunization assays showed that GLA is a more MyD88-biased
agonist of TLR4 for augmenting vaccine-specific immunity.
2. Materials and methods
2.1. Mice and reagents
6–8 week old female C57BL/6 mice were purchased from the Charles River Laboratories.
The strain of B6.B10ScN-Tlr4lps-del/JthJ (designated as TLR4-/-) and C57BL/6J-
Ticam1Lps2/J (designated as TRIF-/-) mice were purchased from the Jackson Laboratory and
maintained in the animal facilities of the California Institute of Technology (Caltech) and
the University of Southern California (USC). B6.129/SvJ-MyD88tm1AKI (designated as
MyD88-/-) mice were a gift from Prof. S. Akira (Osaka University, Osaka, Japan) and
maintained at Caltech and USC. All animal procedures were performed in accordance with
the guidelines set by the National Institutes of Health, Caltech, and USC on the Care and
Use of Animals. The aqueous formulated GLA (GLA-AF, used for in vitro experiments) and
the oil-in-water stable emulsion formulated GLA (GLA-SE, used for in vivo immunization)
[41] were prepared at the Infectious Disease Research Institute (IDRI, Seattle, WA, USA).
2.2. Lentiviral vector construct and production
The lentiviral backbone plasmid FUW-TfROVA was constructed by insertion of the cDNA
consisting of the first 118 amino acids of the membrane-anchoring domain of murine
transferrin receptor) fused downstream with the truncated chicken ovalbumin (OVA, amino
acids 139-386) into FUW [48]; FUW is a HIV-1-derived lentiviral plasmid composed of an
internal human ubiqutin-C promoter to drive transgene expression and woodchuck
responsive element to improve stability of the RNA transcript [49]. We employed a
previously reported procedure of transient transfection of 293T cells to produce the DC-LV-
OVA vector [23]. Briefly, 293T cells cultured in a 15-cm tissue culture plate (BD
Biosciences, San Jose, CA, USA) were transfected via a standard calcium phosphate
precipitation method with the following plasmids: the lentiviral backbone plasmid FUW-
TfROVA (37.5 μg), the plasmid encoding the mutant Sindbis virus glycoprotein (SVGmu)
(18.75 μg), and the packaging plasmids (pMDLg/pRRE and pRSV-Rev, 18.75 μg for each).
The viral supernatants were harvested twice at 48 and 72 h post-transfection, pooled, and
filtered through a 0.45-mm filter (Corning, Lowell, MA, USA). The concentrated viral
pellets were obtained after ultracentrifugation of the viral supernatants at 50,000 ×g for 90
min, and were then resuspended in an appropriate volume of HBSS for in vivo injection.
2.3. BMDC generation and activation
We employed a previously described procedure to generate bone marrow-derived DCs
(BMDCs) with various genetic backgrounds [23]. Briefly, bone marrow from the femurs and
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tibias of mice was grown in RPMI 1640 with 10% heat-inactivated FBS, 2 mM L-glutamine,
100 U/ml penicillin, 100 μg/ml streptomycin, 0.05 mM 2-ME, and 20 ng/ml GM-CSF
(J558L supernatant) after the red blood cells were lysed. Cultures were initiated by placing
107 bone marrow cells in 10 ml of medium onto 100-mm petri dishes (Falcon 1029 plates;
BD Labware, Franklin Lakes, NJ). On day 3, another 10 ml of J558L-conditioned medium
was added. On day 6, suspension cells were collected. BMDCs were seeded at a density of
0.5 million/ml in 24-well plates (BD Labware), treated with GLA-AF (1 μg/ml) or left
untreated, supernatants were collected 24 h later for cytokine measurements. Cells were also
collected for antibody staining and flow cytometric analysis.
2.4. Flow cytometric analysis of surface markers of BMDCs
Single cell suspensions were incubated with anti-mouse CD16/CD32 Fc blocking antibody
and then stained with fluorophore-conjugated monoclonal antibodies against specific BMDC
surface markers, including CD80, CD86, H2-Kb, and I-Ab. All antibodies were purchased
from Biolegend (San Diego, CA). Stained cells were assayed using BD LSRII flow
cytometer (BD Biosciences) and acquired data was analyzed using FlowJo software (Tree
Star, Ashland, OR).
2.5. Supernatant ELISA assay
ELISA was used to detect cytokine/chemokine levels after BMDC activation. Specific
combination of capture and detection antibodies was purchased either from R&D Systems
(Minneapolis, MN) for assaying IL-6, IL-12p70, IL-15, RANTES/CCL5, IP-10/CXCL10,
and IL-1β, or from eBioscience (San Diego, CA) for assaying TNF-α. We followed the
manufacturer's recommended protocols to conduct these ELISA assays.
2.6. Immunization procedure
For immunization with DC-LV, mice were injected with replication-defective DC-LV-OVA
(5×106 Transduction Units (TU)) at the rear footpad. For immunization with adjuvant, GLA-
SE (20 μg) was administered at the base of tail when DC-LV-OVA was injected. For the
experiment to deplete CD4+ T cells, the monoclonal depletion antibody GK1.5 (200 μg,
BioXCell, West Lebanon, NH) was intraperitoneally injected at days 0, 2, 5, and 8 post-
immunization. The vaccinated mice were analyzed for their immune responses 2 wk post-
immunization.
2.7. Intracellular cytokine staining (ICCS)
Splenocytes from immunized or control mice were pooled and incubated with the
OVA257-264 peptide (SIINFEKL) (1μg/ml) in the presence of costimulatory anti-CD28
antibody (2 μg/ml, BD Biosciences) for 2 h at 37 °C in a 96-well round-bottom plate in
RPMI medium supplemented with 10% FBS (Sigma), 10 U/ml penicillin, 100 μg/ml
streptomycin, and 2 mM glutamine. Brefeldin A (BFA, Sigma, St. Louis, MO) was added
(10 μg/ml) to wells to inhibit cytokine exporting for another 4 h. Surface staining was
performed by incubating restimulated cells with anti-mouse CD16/CD32 Fc blocking
antibody, followed by anti-mouse CD8 and anti-mouse CD4 antibodies. Cells were then
permeabilized in 100 μl Cytofix/Cytoperm solution (BD Biosciences) at 4 °C for 10 min,
washed with Perm/Wash buffer (BD Biosciences), and followed by intracellular staining
with PE-conjugated anti-mouse IFN-γ at 4 °C for 15 min. The flow cytometry analysis was
carried out using the FACSort instrument from BD Biosciences. For the multi-parameter
ICCS analysis, cells were stained with the following surface monoclonal antibodies
(Biolegend): anti-CD4-PerCP, anti-CD8-APC-Cy7, anti-CD44-Alexa488, and with the
following intracellular monoclonal antibodies (BD Biosciences): anti-IFN-γ-APC, and anti-
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TNF-α-PE-Cy7. The ICCS data were acquired on a BD LSR II flow cytometer (BD
Biosciences).
2.8. IL-2 ELISPOT assay
ELISPOT assays were performed for detecting IL-2 using a kit from Millipore (Billerica,
MA) according to the manufacturer's instruction. Briefly, anti-mouse IL-2 antibody (10 μg/
ml in PBS) was used as the capture antibody and plated with 100 μl/well on 96-well
MultiScreen-IP plates overnight at 4 °C. The plate was decanted and blocked with the RPMI
medium containing 10% FBS at 37 °C for 2 h. Splenocytes from mice were plated at 5 × 105
cells/well in 100 μl complete medium in company with the CD4 epitope OVA323-339
peptide (ISQAVHAAHAEINEAGR) (10 μg/ml). After 18 h incubation at 37 °C, cells were
lysed and plates were detected by 1 μg/ml biotinylated anti-IL-2 antibody (BD Biosciences)
for 2 h at room temperature. Plates were further washed and incubated with the 1,000-fold-
diluted streptavidin-alkaline phosphate conjugate for 45 min at room temperature. After a
final extensive washing, spots were identified by adding BCIP/NBTplus substrate
(Millipore), and the number of IL-2 producing cells was quantified by an ELISPOT reader.
2.9. Statistics
All the statistics were calculated by either Origin Pro 7.0 or GraphPad Prism 5 software.
Error Bars in all the figures represent SD except the tumor growth curve in therapeutic
tumor challenge model, SEM was used. One-way ANOVA followed by a Bonferroni's
multiple comparison test was used to determine significance of difference while animal
survival curves were analyzed by log-rank (Mantel-Cox) test and the value of P < 0.05 was
considered to be statistically significant.
3. Results
3.1. Activation of dendritic cells by the TLR4 agonist GLA in vitro
Pathogens binding to TLR4 can initiate downstream signal transduction and induce NF-κB
activity, which is critical for DC activation and maturation [50]. To evaluate the activation
status of DCs, we examined the expression of major histocompatibility complex (MHC) and
costimulatory molecules on the surface of BMDCs after GLA stimulation. We used an
aqueous formation of GLA (GLA-AF) for in vitro studies [41, 44]. As shown in the left
panel of Fig. 1A, MHC I (H2-Kb) and MHC II (I-Ab) molecules were both elevated after
GLA treatment, which is likely to enhance DCs’ antigen presentation capability. Expression
of both CD80 and CD86 was enhanced, which should allow DCs to provide stronger
costimulatory signals for T cell stimulation. Furthermore, the surface expression both of
ICAM-1 and CD40 was also greatly increased by GLA treatment (data not shown). To
examine whether activation of DCs by GLA is TLR4-dependent, we conducted a similar
experiment using BMDCs lacking TLR4 expression (TLR4-/- BMDCs). All of these surface
activation markers were unaltered following GLA stimulation of TLR4-/- BMDCs (Fig. 1A,
right panel), confirming that GLA activation of DCs is strictly TLR4-dependent.
We then examined cytokine and chemokine secretion from BMDCs after GLA treatment.
GLA stimulation significantly enhanced production and secretion of interleukin (IL)-6,
TNF-α, RANTES, IP-10, modestly enhanced the amount of IL-1β and IL-12p70, but had
little effect on IL-15 production (Fig. 1B). Proinflammatory cytokines IL-6, TNF-α and
IL-12 are important for promoting the proliferation of CD8+ and CD4+CD25□ T cells, while
limiting CD4+CD25+ regulatory T cell (Treg) proliferation [51-53]. RANTES is known to
be involved in proper T cell function and proliferation [54]. IL-1β can drive proliferation of
CD4+CD25+Foxp3□ effector and memory T cells, while inhibiting CD4+CD25+Foxp3+
Treg function [55]. IL-1β is also involved in CD4+ T cell-dependent antibody production
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and promotes the function of antigen-specific T helper cells [56]. The chemokine IP-10 is
critical for effector T cell trafficking [57] and is involved in promoting T cell-based anti-
tumor immunity [58]. Such elevated secretion of cytokines and chemokines was not
observed in GLA-treated TLR4-/- BMDCs, confirming the essential role of TLR4 for GLA
to activate DCs.
3.2. Adjuvant effect of the TLR4 agonist GLA on DC-LV-induced T cell immunity
We next tested the ability of GLA as an adjuvant to improve OVA-specific CD8+ and CD4+
T cell responses induced by subcutaneous immunization of DC-LV encoding the model
OVA antigen (DC-LV-OVA). OVA was fused with the transferrin receptor transmembrane
sequence for achieving balanced CD4 and CD8 responses [48]. Oil-in-water stable emulsion
formulation of GLA (GLA-SE) was used for all our in vivo studies because such
formulation resulted in more robust adjuvant responses as compared to aqueous GLA [40,
44]. We observed a higher level (approximately 2-3 times higher) of OVA-specific CD8+ T
cells capable of producing IFN-γ and/or TNF-α from GLA-treated group than that of the
untreated control group (Fig. 2A and B). An ELISPOT assay was employed to measure
CD4+ T cell response. We found that GLA-treated mice on average had approximately 2-3
times more IL-2 producing cells than the control mice (Fig. 2B). When the same
immunization protocol was applied to TLR4-/- mice, we observed no enhancement of OVA-
specific CD8+ and CD4+ upon administration of GLA (Fig. 2C and D). This in vivo
immunization study is in good agreement with our in vitro DC activation study, showing
that GLA can bolster the response to a DC-LV-based genetic vaccine in a TLR4-dependent
manner. In addition, in the absence of GLA, we noticed similar levels of OVA-specific
CD8+ and CD4+ T cell responses induced by DC-LV immunization for wild-type and
TLR4-/- mice, suggesting that DC-LV-based immunization generates a fraction of its
vaccine-specific immune response in a manner that is independent of TLR4.
3.3. Adjuvant effect of the TLR4 agonist GLA on DC-LV-induced antibody responses
Because we observed that GLA could improve DC-LV-elicited T cell responses, we
investigated whether GLA could also facilitate vaccine-induced antibody responses. Mice
were immunized with DC-LV-OVA plus and minus GLA adjuvant treatment. Two weeks
post-immunization, sera were collected and OVA-specific titers of different antibody
isotypes (IgG1, IgG2a, IgG2b, IgG3, IgA and IgM) were measured using an ELISA assay.
GLA could broadly and greatly enhance antibody responses induced by DC-LV
immunization (Fig. 3). The generation of elevated titers of both IgG1 (Fig. 3A) and IgG2a
(Fig. 3B) suggests that GLA is likely able to bolster both Th1 and Th2 immune responses.
Interestingly, we observed that GLA could enhance IgA antibody responses as well (Fig.
3E), which may be useful for vaccine applications that require mucosal immunity [59].
Notably, although GLA improved IgM antibody titer (Fig. 3F), the enhancment of IgM titer
was not as significant as that of IgG. This might indicate a role for GLA in facilitating more
efficient isotype switching from IgM to IgG.
3.4. Adjuvant effect of the TLR4 agonist GLA on the anti-tumor immunity delivered by DC-
LV
The promising results of GLA as an adjuvant for enhancing vaccine-specific immune
responses encouraged us to test whether GLA combined with a vector vaccine could
generate better antitumor responses in mice. We employed the EG7 tumor cell line, which
stably expresses chicken OVA, as a tumor model for this investigation [23]. In the tumor
prophylactic model, mice were inoculated with EG7 tumor cells 14 days post-immunization.
Aggressive tumor growth was seen in non-vaccinated control mice. Using the tumor size of
2000 mm3 as a surrogate endpoint of survival, none these mice could survive for more than
20 days. For the group immunized with DC-LV-OVA alone, although all mice developed
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tumors, tumor growth was slower and mice survived longer as compared to the non-
vaccinated group. In contrast, for mice vaccinated with DC-LV-OVA and treated with GLA,
only half of the mice developed tumors and those tumors grew much more slowly than did
those in the vaccine-only group (Fig. 4A), resulting in a longer overall survival for these
tumor-bearing mice (Fig. 4A, lower right). We also evaluated GLA in a therapeutic tumor
model setting. Mice were challenged with a lethal dose of EG7 cells with immunization and
GLA treatment administration 3 days later (Fig. 4B). As compared to the vaccine-only
group, significantly slower tumor growth was observed for mice that received both DC-LV-
OVA and GLA treatment and median survival time was 8 days longer (Fig. 4B, lower
panel).
3.5. Role of CD4+ T cells in GLA-augmented DC-LV immunization
It is well documented that CD4+ T helper cells play a pivotal role in orchestrating the
generation of both effector and memory CD8+ cytotoxic T cells [60, 61], although CD8+ T
cell responses can also be produced in a CD4+ T cell-independent manner [62-64]. To
investigate the cellular mechanism underlying the enhanced vaccine responses delivered by
GLA, we conducted experiments to deplete CD4+ T cells following the immunization. Four
groups of mice were immunized with DC-LV-OVA, within which two groups also received
GLA adjuvant at the same time. Depletion of CD4+ T cells by the GK1.5 antibody was
carried out in one vaccinated group and in a group vaccinated along with GLA treatment.
Flow cytometric analysis of the resulting splenocytes showed that the majority of CD4+ T
cells (21.5% vs. 0.33%, Fig. 5A) were eliminated by the antibody treatment and these mice
maintained such a depletion condition throughout the experiment. The intracellular staining
of CD8+ T cells harvested from immunized mice for IFN-γ (Fig. 5B) showed higher (~19%
vs. ~7%) OVA-specific CD8+ T cells in mice with the GLA-adjuvanted vaccination. On the
contrary, with the CD4+ T cell depletion, the immune response dropped to about 2% and
GLA treatment failed to improve the CD8+ T cell response in the CD4+ T cell-deficient
condition (Fig. 5A and B). This data demonstrates that CD4+ T cells are necessary for the
adjuvanting effect of GLA on lentiviral vector immunization. We also observed that the DC-
LV-OVA-induced CD8+ T cell response was partially dependent on the presence of CD4+ T
cells (Fig. 5A, DC-LV-OVA vs. DC-LV-OVA/GK1.5). To investigate whether such
dependence is unique for DC-LV, we directly compared immunization by vectors enveloped
with either SVGmu (DC-LV) or the glycoprotein derived from vesicular stomatitis virus
(VSVG), which provides a broader tropism in both normal and CD4+ T cell-deficient
conditions. Consistent with our previous results [23], when immunized with an identical
dose, the SVGmu-enveloped vector (DC-LV) elicited a markedly higher CD8+ T cell
response than that induced by the VSVG-enveloped vector (Fig. 5C). Depletion of CD4+ T
cells lowered CD8+ T cell immunity in both situations, although the drop was more
significant for SVGmu-enveloped vector than VSVG-enveloped vector (Fig. 5C).
3.6. Study of the role of MyD88 and TRIF pathways in GLA-mediated activation of DCs in
vitro
It has been reported that Monophosphoryl Lipid A (MPL), another TLR4 agonist, activates
macrophage cells in a TRIF-biased rather than MyD88-biased manner when compared with
its parent molecule LPS [65]. Because GLA is a relatively novel and unstudied synthetic
molecule, elucidating the downstream signaling pathway involved for activating DCs by
GLA can be very useful for understanding the mechanism of its adjuvant effect and
exploring its potential applications in vaccine research. Among various Toll-like receptors,
TLR4 is the only receptor that utilizes both TRIF- and MyD88-dependent pathways for
signaling [32, 35]. To examine which pathway GLA/TLR4 depends on to trigger DC
activation, BMDCs derived from wild-type, MyD88-/- and TRIF-/- mice were generated and
treated with GLA for 1 day individually; no GLA treatment was included as controls.
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Treated BMDCs were subjected to analysis of their surface expression of costimulatory
molecules (CD40, CD80, CD86, OX40), MHC class I molecule H2-Kb, and MHC class II
molecule I-Ab. As shown in Fig. 6A, expression of these surface markers on both MyD88-/-
and TRIF-/- BMDCs were generally lower (except CD80 which has similar levels in all three
situations) than those expressed on wild-type cells after GLA treatment, indicating that
MyD88 and TRIF both participated in the downstream signaling in response to GLA
stimulation. To further this study, we collected supernatants from these BMDCs and assayed
the secretion profile of a selective set of cytokines and chemokines (Fig. 6B). Surprisingly,
lack of MyD88 expression almost completely abolished the ability of GLA-treated DCs to
produce cytokines TNF-α, IL-6, and IL-1β, while they were able to maintain a modest
production of chemokines RANTES and IP-10. On the other hand, as compared to MyD88-
null cells, TRIF-/- BMDCs better retained the ability to secrete TNF-α, IL-6, and IL-1β in
response to GLA treatment, although their levels of secretion were lower than that of the
wild-type cells. This suggests that the production of these cytokines is less dependent on the
TRIF-mediated pathway. In contrast, chemokines RANTES and IP-10 tend to depend more
on TRIF expression because TRIF-/- BMDCs produced less of them compared to MyD88-/-
cells upon GLA stimulation. Interestingly, we observed that DCs have an equal, partial
dependence on MyD88 and TRIF for the secretion of IL-12 in response to GLA stimulation.
3.7. Study of the role of MyD88 and TRIF pathways in GLA-mediated activation of DCs in
vivo
To examine the in vivo role of GLA adjuvant in augmenting DC-LV-based vaccination, we
compared immune responses among vaccinated MyD88-/-, TRIF-/-, and wild-type mice. As
seen previously, intracellular cytokine staining of splenocytes restimulated with the
OVA257-264 peptide showed enhanced CD8+ T cell immunity in wild-type mice treated with
GLA (Fig. 7A). Significantly lower antigen-specific CD8+ T cell immune responses were
observed in MyD88-/- mice and GLA treatment did not improve the magnitude of the
response (Fig. 7A and B). In sharp contrast, TRIF-/- mice could mount the same level of
CD8+ T cell response as that of wild-type animals and a similarly enhanced level of immune
responses was obtained upon GLA treatment. These results indicate that the MyD88
pathway, rather than the TRIF pathway, is essential for GLA-adjuvanted CD8+ T cell
responses in vivo. We also assessed the OVA-specific CD4+ T cell immunity by an IL-2
ELISPOT assay for these treated mouse groups and found a similar trend to what was
observed for CD8+ T cell responses (Fig. 7B, lower right), suggesting that GLA-enhanced
CD4+ T cell immune response in vivo is also largely dependent on the MyD88 pathway.
Another notable observation from this study is the important role of MyD88 in generating
vaccine-specific immunity induced by DC-LV immunization. Comparing to the wild-type
mice, the MyD88-/- mice had a markedly diminished CD8+ and CD4+ T cell responses after
immunization, while TRIF-deficient mice could retain the similar level of the response
magnitude (Fig. 7B). All of these data suggest that MyD88 rather than TRIF plays an
important signaling transduction role for DC-LV vaccine to generate immune responses to
immunogens in vivo.
4. Discussion
Antigen genes delivered to DCs by replication-deficient LVs generate both antigen-specific
T cell and B cell responses in mice and rhesus macaques [1, 66]. Skin-derived DCs are the
major cell targets for LV-based immunization [13-15]. However, several studies have shown
that LVs are weak stimulators for activation of DCs by themselves [67], and further
activation is needed [68, 69]. Activation of individual TLRs or combined TLRs could be
incorporated in order to achieve stronger T cell responses [70-74]. We have developed a
DC-targeted LV vector system where LVs are enveloped with an engineered Sindbis virus
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glycoprotein. This DC-LV system can target DCs through interaction with DC-SIGN and
subcutaneous immunization with this vector has induced strong antigen-specific immunity
[23]. Our in vitro study revealed that DC-SIGN-interacting DC-LV only modestly induces
maturation of DCs [23]. Therefore, it is possible that further activation of DCs would
improve the immune responses induced by DC-LV. Here we demonstrate that the synthetic
TLR4 agonist GLA can be used as adjuvant to enhance DC-LV-mounted immune responses.
Some studies reported that LV-mediated transduction efficiency towards DCs could be
reduced with prior to or simultaneous activation of DCs [75]. Other studies showed that
transduction of LVs did not hamper the subsequent activation of DCs by TLRs [76]. The
possible explanation is that upon maturation, internalization potency of DCs is down-
regulated [77, 78], which may cause the reduced transduction. In light of these observations,
we decided to employ a protocol to deliver LVs and GLA at different locations (footpad vs.
base of tail). After administration, GLA could be transported to lymph nodes through
lymphatic circulation and encounters DCs that have been modified by LVs. In addition,
GLA could activate DCs that have not been transduced by LVs; these DCs could
subsequently migrate to the lymph nodes to not only secrete inflammatory cytokines but also
cross-prime antigens derived from LV-modified DCs through cross antigen presentation,
which could eventually also enhance antigen-specific immunity.
Three signals are required for efficient stimulation of T cells by DCs: 1) an antigen-specific
signal, involving the interaction of the MHC/peptide complex with T cell receptor (TCR); 2)
a surface costimultory protein on DCs interacting with a receptor on T cells; and 3) a
cytokine signal passed from DC to T cell [79, 80]. Our in vitro activation study, presented in
Fig. 1, indicated that molecular signatures involved in all these three signals could be
enhanced after BMDCs were treated by GLA, including the upregulation of MHC
molecules, elevated expression of costimulatory molecules CD80 and CD86, and improved
production of proinflammatory cytokines (IL-6, TNF-α, IL-12, and IL-1β) and chemokines
(RANTES/CCL5 and IP-10/CXCL10); a comparable potency was observed upon LPS
stimulation (data not shown). This is consistent with prior studies, in which either murine
and human monocyte/macrophage cell lines [44] or murine BMDCs [41] secreted TNF-α,
IL-6, and IP-10 in response to aqueous GLA stimulation. GLA-mediated DC maturation is
TLR4-dependent, as the TLR4-/- BMDCs failed to respond to GLA. Our use of genetically
deficient cells to directly demonstrate the TLR4 dependence of GLA complements previous
use of anti-TLR4 antibody to successfully block GLA-mediated activation [44]. To further
improve DCs potency, combination strategy of TLRs with silencing of inhibitory pathways
[51, 80] can also be taken into consideration.
Both CD8+ cytotoxic and CD4+ T helper cells act coordinately to either kill tumor cells or
clear infectious pathogens. In our study, we found that by co-administration of GLA along
with DC-LV immunization, numbers of both CD8+ and CD4+ T cells specific for OVA
antigen were greatly increased in mice. We confirmed that the enhancement is strictly
TLR4-dependent, as no elevated response to GLA was seen in TLR4-deficient mice. In
addition to T cell immunity, the antibody response is also important to clear infectious
viruses and initiate Fc-mediate tumor cell killing by natural killer (NK) cells [81]. We found
that GLA improved the titers of various antibody isotypes specific for OVA, including that
of both IgG1 and IgG2a, indicating that GLA can boost both the Th1 and Th2 responses. We
observed an enhanced IgA antibody titer, suggesting that GLA can be used as an adjuvant to
facilitate the application of DC-LV vaccination for inducing mucosal immunity.
CD4+ T cells provide essential help to CD8+ T cell during the priming stage to generate
effector and memory CD8 T cell responses [60, 61, 82]. On the other hand, it was reported
that helper-independent cytotoxic T cell priming can be promoted by upregulating CD40L
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expression on DCs, and only TLR3 and TLR9, but not TLR2 and TLR4, have the capacity
to stimulate CD40L expression [83]. This suggests that GLA, as a TLR4 agonist, may
promote CD8+ cytotoxic T cell response in a CD4+ T helper cell-dependent manner. There
are several hypotheses and models regarding how CD4+ T cells provide help to CD8+ T
cells through APCs. One of them requires that activated CD4+ T cells and CD8+ T cells
interact with the same APC [84, 85]. Another model is that CD4+ T cells can acquire the
MHC-peptide complexes and costimulatory molecules from APCs, and then these CD4+ T
cells carrying acquired antigen presentation components can efficiently stimulate CD8+ T
cells [86]. We conducted a simple CD4+ T cells depletion experiment to study their role in
GLA promotion of the CD8+ T cell response. Our results show that without help from CD4+
T cells, the CD8+ T cell response cannot be augmented by GLA. Either model could explain
the involvement of CD4+ T cells with the adjuvant effect of GLA possibly dependent on
CD4+ T cells to indirectly pass signals to CD8+ T cells. Interestingly, we also found that
GLA failed to improve immune responses induced by DC-LV encoding the unmodified
OVA sequence (without transferrin receptor membrane-binding segment) (Fig. S1).
Considering that a much lower OVA-specific CD4+ T cell response is elicited with such an
antigen configuration, it seems that the presence of immunogen-specific CD4+ T cells is
vital for GLA to augment DC-LV-based vaccination. We also observed that CD4+ T cells
play a critical role in generating primary CD8+ T cell responses induced by either DC-LV or
VSVG-enveloped LVs, and depletion of CD4+ T cells markedly reduced vaccine-specific
CD8+ T cell responses in either case. This is in good agreement with a recent report showing
the important role of CD4+ T cells in LV-mediated immunization [15].
Activation of TLR4 triggers two different signaling pathways controlled respectively by
MyD88/MAL, which is critical for regulating proinflammatory cytokines production, and
TRIF/TRAM, which is responsible for mediating the induction of Type I interferons [32,
35]. Many of these signaling studies have been conducted in macrophage cells. One recent
study compared MPL with LPS in mouse macrophages and showed that MPL is a more
TRIF-biased TLR4 agonist and preferentially induces TRIF-mediated signals for
macrophage activation [65]. However, their subsequent studies in BMDCs demonstrated
that both MyD88 and TRIF pathways are involved in the MPL-mediated activation of DCs
[87]. Shen et al. found that induction of both MyD88 and TRIF signaling pathways are
critical for maximizing the capacity of DCs for T cells priming [36]. We found that GLA
activates BMDCs in vitro in both MyD88- and TRIF-dependent pathways. This represents
the first study to use genetically deficient DCs (MyD88-/- and TRIF-/-) to investigate
signaling activation of GLA in DCs, and the data corroborates the result from a mouse
inflammation microarray study that showed both MyD88- and TRIF-inducible genes
responding to GLA stimulation [41]. In contrast, in our in vivo data we observed a more
MyD88-biased signaling role for GLA to elicit adjuvant responses to DC-LV immunization.
It is unknown whether the MyD88-biased role is unique for the interplay between GLA and
DC-LV or it is more general and can be seen in other formats of vaccine delivery; more
experiments are required to address these questions. One possible explanation is found in the
behavior of the cytokines IL-6 and TNF-α, which appears to be key cytokines for priming
CD8+ T cell responses in vivo [51]. Our in vitro study showed that MyD88-/- BMDCs
almost completely lacked secretion of TNF-α and IL-6, while TRIF-/- BMDCs could still
respond to GLA treatment and secrete a significant level of these two cytokines. An inability
of MyD88-/- BMDCs to produce these cytokines in response to GLA could partially explain
the strong dependence on the MyD88-dependent pathway for GLA augmentation of
vaccine-specific immunity in vivo.
Xiao et al. Page 10
Vaccine. Author manuscript; available in PMC 2013 March 28.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
5. Conclusion
We have determined that GLA can activate DCs in vitro and augment humoral and cellular
immunity elicited by DC-LV immunization in a TRL4-dependent manner. CD4+ helper T
cells are indispensible for this adjuvant effect of GLA. Our in vitro assays confirm that both
MyD88 and TRIF are able to participate in downstream signaling under GLA-mediated
activation of DCs, but our in vivo immunization of genetically deficient mice by DL-LV
suggests that MyD88 plays the greater role in mediating potent adjuvant effects of GLA to
improve antigen-specific immune responses.
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Fig. 1.
GLA-mediated activation of mouse BMDCs in vitro. A. FACS analysis of surface antigen
presentation and costimulatory molecules of CD11c+ BMDCs from wild-type mouse (left)
and TLR4-/- mouse (right) treated with aqueous GLA (solid line) or aqueous formulation
lacking GLA (shaded area) for 24 h. Representative data from triplicate cultures is shown.
B. Secretion of cytokines and chemokines of BMDC cultures from wild-type (black bar) and
TLR4-/- mice (white bar) treated with (+) or without (□) GLA. Mean secretion +/- SD of
triplicate culture is shown.
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Fig. 2.
Adjuvant effects of GLA on boosting DC-LV-based vaccine-specific T cell immune
responses in vivo. Wild-type (A, B) or TLR4-/- (C, D) mice were immunized at rear footpad
with PBS, DC-LV-OVA, DC-LV-OVA plus GLA-SE (base of tail). 14 d later, splenocytes
were collected and OVA-specific CD8+ T cells were analyzed by intracellular staining for
IFN-γ or TNF-α expression after stimulation with OVA257-264 peptide for 6 h (A, C). The
FACS data shown is one representative data of four analyzed mice. (B, D) Statistical data
showing the percentage of IFN-γ+, TNF-α+, or IFN-γ+TNF-α+ cells within the CD8+ T cell
population. Splenocytes were also pooled for an ELISPOT assay to analyze IL-2 secretion
following stimulation with OVA323-339 peptide for 18 h. (***: P < 0.001; **: P < 0.01; *: P
< 0.05 and n/s: not statistically significant; One-way ANOVA followed by a Bonferroni's
multiple comparison test. Mean + SD is shown.)
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Fig. 3.
Adjuvant effects of GLA on boosting DC-LV-based vaccine-specific antibody immune
responses in vivo. ELISA of OVA-specific IgG1 (A), IgG2a (B), IgG2b (C), IgG3 (D), IgA
(E), IgM (F) antibody titers in sera of mice 14 d after immunization with DC-LV-OVA (left)
or DC-LV-OVA plus GLA-SE (right). Results are shown as mean titer + SD of four mice
per group. (*: P < 0.05; One-way ANOVA followed by a Bonferroni's multiple comparison
test.)
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Fig. 4.
Adjuvant effects of GLA on DC-LV immunization to enhance antitumor immune responses.
(A, upper) Schematic showing the immunization and tumor challenge strategy in the
prophylactic model. (A, middle and lower left) Mice were vaccinated with PBS (four mice),
DC-LV-OVA (six mice), or DC-LV-OVA plus GLA-SE (six mice) on day 0, followed by
EG7 tumor challenge on day 14. Tumor growth was quantified as tumor volume (mm3) and
plotted as a function of days after inoculation of EG7 cells. Three of the DC-LV-OVA plus
GLA-SE mice never developed tumors. (A, lower right) Kaplan-Meier survival plot of mice
vaccinated with PBS (●), DC-LV-OVA (■), or DC-LV-OVA plus GLA-SE (▲), P <
0.0001. The tumor size of 2000 mm3 was used as a surrogate endpoint of survival. (B,
upper) Schematic showing the tumor inoculation on day 0 and immunization strategy on day
3 in the therapeutic model. (B, middle) Tumor growth was plotted as mean volume +/- SEM
(n=10) as a function of days after EG7 tumor challenge. (B, lower) Kaplan-Meier survival
plot of mice vaccinated with DC-LV-OVA (■) or DC-LV-OVA plus GLA-SE (▲), P <
0.0001.
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Fig. 5.
The role of CD4+ helper T cells in GLA-enhanced CD8+ T cell responses. A. FACS analysis
of intracellular staining of IFN-γ from splenocytes of mice immunized with PBS, DC-LV-
OVA, DC-LV-OVA plus GK1.5 antibody-mediated depletion of CD4+ T cells, or DC-LV-
OVA plus GLA-SE and GK1.5. One representative data from a group of four mice is shown.
Percentage shown in the left panel is the percentage of CD4+ T cells and CD8+ T cells. B.
Statistical data showing OVA-specific CD8+ T cells by intracellular staining of IFN-γ
following stimulation with OVA257-264 peptide. C. OVA-specific CD8+ T cell percentage by
intracellular staining of IFN-γ after OVA257-264 peptide stimulation from mice immunized
for 14 d with the same transduction units (TUs) of either SVGmu- (left) or VSVG- (right)
enveloped LV-OVA. Black bar: isotype control antibody; white bar: GK1.5 antibody. (***:
P < 0.001; **: P < 0.01; *: P < 0.05 and n/s: not statistically significant; One-way ANOVA
followed by a Bonferroni's multiple comparison test. Mean +/- SD is shown.)
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Fig. 6.
Involvement of MyD88 and TRIF signaling pathways in GLA-mediated activation of
BMDCs in vitro. A. FACS analysis of surface activation markers of CD11c+ BMDCs from
wild-type mouse (black), MyD88-/- mouse (white), or TRIF-/- mouse (dashed line) treated
with (+) or without (□) aqueous GLA. Data is shown based on either percentage or
normalized mean fluorescence intensity (MFI). B. Secretion of cytokines and chemokines of
BMDCs derived from wild-type (black), MyD88-/- (white), or TRIF-/- mouse (dashed line)
stimulated with (+) or without (□) GLA. The mean secretion +/- SD of triplicate culture is
shown.
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Fig. 7.
Involvement of MyD88 and TRIF signaling pathways in GLA-adjuvanted DC-LV
immunization in vivo. A. Wild-type (upper), MyD88-/- (middle), and TRIF-/- (lower) mice
were immunized with DC-LV-OVA, or DC-LV-OVA plus GLA-SE. 2 wk later, OVA-
specific CD8+ T cells were analyzed by intracellular staining of IFN-γ following
OVA257-264 peptide stimulation. The FACS data shown is representative of four mice tested.
B. Statistical data showing OVA-specific CD8+ T cells analyzed by IFN-γ+ (upper left),
TNF-α+ (upper right), or IFN-γ+TNF-α+ (lower left) populations for groups of mice
described above with (+) or without (-) GLA treatment. (B, lower right) Splenocytes were
also pooled for an ELISA assay of IL-2 production after stimulation with OVA323-339
peptide. (**: P < 0.01; *: P < 0.05 and n/s: not statistically significant; One-way ANOVA
followed by a Bonferroni's multiple comparison test. Mean +/-SD is shown.)
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